CoChat

Key determinants of target DNA recognition by retroviral intasomes

Open access

The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Retroviral integration favors weakly conserved palindrome sequences at the sites of viral DNA joining and generates a short (4-6 bp) duplication of host DNA flanking the provirus. We previously determined two key parameters that underlie the target DNA preference for prototype foamy virus (PFV) and human immunodeficiency virus type 1 (HIV-1) integration: flexible pyrimidine (Y)/purine (R) dinucleotide steps at the centers of the integration sites, and base contacts with specific integrase residues, such as Ala188 in PFV integrase and Ser119 in HIV-1 integrase. Here we examined the dinucleotide preference profiles of a range of retroviruses and correlated these findings with respect to length of target site duplication (TSD). RESULTS: Integration datasets covering six viral genera and the three lengths of TSD were accessed from the literature or generated in this work. All viruses exhibited significant enrichments of flexible YR and/or selection against rigid RY dinucleotide steps at the centers of integration sites, and the magnitude of this enrichment inversely correlated with TSD length. The DNA sequence environments of in vivo-generated HIV-1 and PFV sites were consistent with integration into nucleosomes, however, the local sequence preferences were largely independent of target DNA chromatinization. Integration sites derived from cells infected with the gammaretrovirus reticuloendotheliosis virus strain A (Rev-A), which yields a 5 bp TSD, revealed the targeting of global chromatin features most similar to those of Moloney murine leukemia virus, which yields a 4 bp duplication. In vitro assays revealed that Rev-A integrase interacts with and is catalytically stimulated by cellular bromodomain containing 4 protein. CONCLUSIONS: Retroviral integrases have likely evolved to bend target DNA to fit scissile phosphodiester bonds into two active sites for integration, and viruses that cut target DNA with a 6 bp stagger may not need to bend DNA as sharply as viruses that cleave with 4 bp or 5 bp staggers. For PFV and HIV-1, the selection of signature bases and central flexibility at sites of integration is largely independent of chromatin structure. Furthermore, global Rev-A integration is likely directed to chromatin features by bromodomain and extraterminal domain proteins.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12977-015-0167-3

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Sequence logos and dinucleotide step analysis of integration sites with 4 bp TSDs. (A-D) The height of each individual base at a given position is proportional to the frequency of the corresponding nucleotide within the sequences represented by the logos, and the height of each stack of base logos reflects the level of conservation at that position. (E) Percent YR utilization across the integration sites from panels A-D is shown relative to the calculated random value of 22% (dotted gray horizontal line). (F) Same as in panel E, except that the graph depicts RY utilization across the integration sites. Statistical analysis of panel E and F results are shown in Additional file 2: Figure S2 panels A and B, respectively. (G and H) The percent of YR (panel G) and RY (panel H) enrichment for each virus compared to random.
Figure 1 Sequence logos and dinucleotide step analysis of integration sites with 4 bp TSDs. (A-D) The height of each individual base at a given position is proportional to the frequency of the corresponding nucleotide within the sequences represented by the logos, and the height of each stack of base logos reflects the level of conservation at that position. (E) Percent YR utilization across the integration sites from panels A-D is shown relative to the calculated random value of 22% (dotted gray horizontal line). (F) Same as in panel E, except that the graph depicts RY utilization across the integration sites. Statistical analysis of panel E and F results are shown in Additional file 2: Figure S2 panels A and B, respectively. (G and H) The percent of YR (panel G) and RY (panel H) enrichment for each virus compared to random.CC BY · PubMed Central
Figure 2 Sequence logos and dinucleotide step analysis of integration sites from retroviruses that yield 5 bp TSDs. Sequence logos for HIV-1 (A), EIAV (B), SIV (C), and Rev-A (D). (E) YR step analysis for the integration sites depicted in panels A-D. (F) Same as in panel E, except RY dinucleotide frequencies were calculated. Statistical analyses of panel E and F results are depicted in Additional file 2: Figure S2 panels C and D, respectively. Percent YR and RY enrichment for each virus compared to random is shown in (G) and (H), respectively. Other labeling is as in Figure 1.
Figure 2 Sequence logos and dinucleotide step analysis of integration sites from retroviruses that yield 5 bp TSDs. Sequence logos for HIV-1 (A), EIAV (B), SIV (C), and Rev-A (D). (E) YR step analysis for the integration sites depicted in panels A-D. (F) Same as in panel E, except RY dinucleotide frequencies were calculated. Statistical analyses of panel E and F results are depicted in Additional file 2: Figure S2 panels C and D, respectively. Percent YR and RY enrichment for each virus compared to random is shown in (G) and (H), respectively. Other labeling is as in Figure 1.CC BY · PubMed Central
Figure 3 Sequence logos and YR/RY dinucleotide selectivities of viral integration sites with 6 bp TSDs. Sequence logos are shown for conglomerate integration sites of ASLV (A), HERV-K (B), HTLV-1 (C), and MMTV (D). (E) YR frequency utilization across the integration sites of viruses depicted in panels A-D. (F) Same as in panel E, except the plot is for RY dinucleotide utilization. Statistical analyses of panel E and F results are shown in Additional file 2: Figure S2 panels E and F, respectively. The percent YR and RY enrichment for each virus compared to random is in (G) and (H), respectively. Other labeling is as in Figure 1.
Figure 3 Sequence logos and YR/RY dinucleotide selectivities of viral integration sites with 6 bp TSDs. Sequence logos are shown for conglomerate integration sites of ASLV (A), HERV-K (B), HTLV-1 (C), and MMTV (D). (E) YR frequency utilization across the integration sites of viruses depicted in panels A-D. (F) Same as in panel E, except the plot is for RY dinucleotide utilization. Statistical analyses of panel E and F results are shown in Additional file 2: Figure S2 panels E and F, respectively. The percent YR and RY enrichment for each virus compared to random is in (G) and (H), respectively. Other labeling is as in Figure 1.CC BY · PubMed Central
Figure 4 Sequence logos for PFV and HIV-1 integration sites in nucleosome-free versus chromatinized tDNA. (A) The logo illustrates the average nucleotide sequence of the first 50 nucleotides of center-aligned nucleosomal DNA sequences isolated from chicken erythrocytes [68]. (B) PFV integration sites derived from virus-infected cells [92,93]. (C) Integration sites from recombinant PFV intasomes and deproteinized cellular DNA. (D) HIV-1 integration sites from virus-infected cells [87]. (E) Concerted HIV-1 integration sites from recombinant HIV-1 IN and naked pGEM9Zf(−) plasmid DNA [33].
Figure 4 Sequence logos for PFV and HIV-1 integration sites in nucleosome-free versus chromatinized tDNA. (A) The logo illustrates the average nucleotide sequence of the first 50 nucleotides of center-aligned nucleosomal DNA sequences isolated from chicken erythrocytes [68]. (B) PFV integration sites derived from virus-infected cells [92,93]. (C) Integration sites from recombinant PFV intasomes and deproteinized cellular DNA. (D) HIV-1 integration sites from virus-infected cells [87]. (E) Concerted HIV-1 integration sites from recombinant HIV-1 IN and naked pGEM9Zf(−) plasmid DNA [33].CC BY · PubMed Central
Figure 5 Flexibility profiles for PFV and HIV-1 integration sites in nucleosome-free versus chromatinized tDNA. (A and B) YR and RY frequency charts, respectively, for PFV integration sites into deproteinized genomic DNA (PFV in vitro) and from virus infection. Vertical dotted black line represents central dinucleotide step(s), and horizontal dotted grey line represents the MRC frequency of YR/RY utilization. (C and D)) Bar graphs illustrating the percent YR and RY enrichment, respectively, at the central dinucleotide step relative to MRC values. (E and F) YR and RY frequency charts, respectively, for HIV-1 integration sites into naked plasmid DNA (HIV-1 in vitro) and from virus infection. (G and H) Bar graphs illustrating the percent YR and RY enrichment, respectively, at the central dinucleotide steps compared to MRC.
Figure 5 Flexibility profiles for PFV and HIV-1 integration sites in nucleosome-free versus chromatinized tDNA. (A and B) YR and RY frequency charts, respectively, for PFV integration sites into deproteinized genomic DNA (PFV in vitro) and from virus infection. Vertical dotted black line represents central dinucleotide step(s), and horizontal dotted grey line represents the MRC frequency of YR/RY utilization. (C and D)) Bar graphs illustrating the percent YR and RY enrichment, respectively, at the central dinucleotide step relative to MRC values. (E and F) YR and RY frequency charts, respectively, for HIV-1 integration sites into naked plasmid DNA (HIV-1 in vitro) and from virus infection. (G and H) Bar graphs illustrating the percent YR and RY enrichment, respectively, at the central dinucleotide steps compared to MRC.CC BY · PubMed Central
Figure 6 BRD4 protein and interaction with Rev-A IN. (A) Schematic of human BRD4 isoform C (NCBI reference sequence NP_055114.1) highlighting various protein domains and the 426–720 fragment used in this study. (B) Ni-NTA pull-down of purified BRD4462–720 by His6-tagged Rev-A IN. Migration positions of standards (in kDa) are labeled to the left. Lanes 1–4: 20% reaction input of the indicated proteins. Lanes 5 and 6: the indicated BRD4462–720 protein was incubated with Ni-NTA beads in the absence of Rev-A IN. Lanes 7 and 8: the indicated BRD4462–720 protein was incubated with Rev-A IN-bound beads. The gel is representative of results obtained from three independent experiments.
Figure 6 BRD4 protein and interaction with Rev-A IN. (A) Schematic of human BRD4 isoform C (NCBI reference sequence NP_055114.1) highlighting various protein domains and the 426–720 fragment used in this study. (B) Ni-NTA pull-down of purified BRD4462–720 by His6-tagged Rev-A IN. Migration positions of standards (in kDa) are labeled to the left. Lanes 1–4: 20% reaction input of the indicated proteins. Lanes 5 and 6: the indicated BRD4462–720 protein was incubated with Ni-NTA beads in the absence of Rev-A IN. Lanes 7 and 8: the indicated BRD4462–720 protein was incubated with Rev-A IN-bound beads. The gel is representative of results obtained from three independent experiments.CC BY · PubMed Central
Figure 7 Concerted integration activity of Rev-A IN. (A) Ethidium bromide stained image of Rev-A IN integration reactions in the presence of increasing concentrations of indicated BRD4462–720 protein. Migration positions of standards (in kb) are shown to the left, and the positions of single vDNA end, or half-site, and concerted vDNA integration products, as well as supercoiled (s.c.) and open circular (o.c) forms of the plasmid tDNA, are to the right. Lanes 1 and 2: Rev-A IN and tDNA incubated without vDNA or with vDNA, respectively. Lanes 3–6: increasing concentrations (0.05, 0.15, 0.35, 0.5 μM) of BRD4462–720 incubated with Rev-A IN plus vDNA and tDNA. Lanes 7–10: same as lanes 3–6 but with BRD4462–720/L630E. (B) Strand transfer activities for three independent experiments ± standard error of the mean, measured by quantification of DNA band intensity. The results were normalized to the level of Rev-A IN concerted integration activity in the absence of BRD4462–720 proteins, which was set to 100%. P values of <0.05 and <0.01 are indicated by * and **, respectively, as determined by one-tailed t-test.
Figure 7 Concerted integration activity of Rev-A IN. (A) Ethidium bromide stained image of Rev-A IN integration reactions in the presence of increasing concentrations of indicated BRD4462–720 protein. Migration positions of standards (in kb) are shown to the left, and the positions of single vDNA end, or half-site, and concerted vDNA integration products, as well as supercoiled (s.c.) and open circular (o.c) forms of the plasmid tDNA, are to the right. Lanes 1 and 2: Rev-A IN and tDNA incubated without vDNA or with vDNA, respectively. Lanes 3–6: increasing concentrations (0.05, 0.15, 0.35, 0.5 μM) of BRD4462–720 incubated with Rev-A IN plus vDNA and tDNA. Lanes 7–10: same as lanes 3–6 but with BRD4462–720/L630E. (B) Strand transfer activities for three independent experiments ± standard error of the mean, measured by quantification of DNA band intensity. The results were normalized to the level of Rev-A IN concerted integration activity in the absence of BRD4462–720 proteins, which was set to 100%. P values of <0.05 and <0.01 are indicated by * and **, respectively, as determined by one-tailed t-test.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 106 references

Cited by

See all 75

Metadata

Authors
Serrao, E., Ballandras-Colas, A., Cherepanov, P., Maertens, G. N., & Engelman, A. N.
Affiliations
  • Dana-Farber Cancer Institute (US)
  • The Francis Crick Institute (GB)
  • Imperial College London (GB)
Corresponding author
Engelman, Alan N
Venue
Retrovirology
Published
2015-04-30
Volume
12
Issue
1
Pages
39-39
ISSN
1742-4690 (ISSN-L)
OpenAlex
W2109570247
Cited by
62
References
106
Citations by year
2026: 3 · 2023: 2 · 2022: 6 · 2021: 8 · 2020: 6 · 2019: 6 · 2018: 6 · 2017: 6 · 2016: 15 · 2015: 4
FWCI
7.06
Type
journal article
Language
en
Open access
Locations
  • Retrovirology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • Harvard University
  • Harvard University Center for AIDS Research (AI060354)
  • Francis Crick Institute (10061)
  • National Institutes of Health (AI060354)
  • Center for AIDS Research, University of Washington (AI060354)
  • National Institute of Allergy and Infectious Diseases (AI060354, R01AI070042, AI070042, P30AI060354)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Keywords
retroviral integration, integrase, target site duplication, HIV-1 integrase, Moloney murine leukemia virus, chromatin, bromodomain proteins, DNA bending
MeSH terms
Cell Line, DNA, Humans, HIV-1, Spumavirus, Virus Integration, Integrases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Key determinants of target DNA recognition by retroviral intasomes. https://app.cochat.ai/papers/10.1186/s12977-015-0167-3
The paper
Serrao, E., Ballandras-Colas, A., Cherepanov, P., Maertens, G. N., & Engelman, A. N. (2015). Key determinants of target DNA recognition by retroviral intasomes. Retrovirology. https://doi.org/10.1186/s12977-015-0167-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.